Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily
(od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation
therapy with a lower risk of bleeding in patients with atrial fibrillation associated with at
least one major cardiovascular risk factor.Primary objectives :The combination of clopidogrel
plus aspirin compared to adjusted dose (INR between 2.0 and 3.3) oral anticoagulation (a
vitamin K antagonist) will result in the same risk of the composite outcome of stroke,
non-CNS systemic embolism, myocardial infarction or vascular death in patients with atrial
fibrillation.The secondary objective is to establish whether or not aspirin plus clopidogrel
has a lower risk of hemorrhage than standard anticoagulation therapy.